tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Ovid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
PremiumRatingsOvid Therapeutics: Strategic Advances and Promising Developments Justify Buy Rating
23d ago
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
Premium
Company Announcements
Ovid Therapeutics Transfers Stock to Nasdaq Capital Market
24d ago
Ovid Therapeutics reports Q2 EPS (6c), consensus (15c)
Premium
The Fly
Ovid Therapeutics reports Q2 EPS (6c), consensus (15c)
24d ago
Ovid Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany AnnouncementsOvid Therapeutics Approves Key Proposals at Annual Meeting
2M ago
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
Premium
Company Announcements
Ovid Therapeutics Sells Ganaxolone Royalties to Immedica
2M ago
Ovid enters agreement with Immedica for sale of future ganaxolone royalties
Premium
The Fly
Ovid enters agreement with Immedica for sale of future ganaxolone royalties
2M ago
Ovid Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright
PremiumThe FlyOvid Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright
3M ago
Ovid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
Premium
Ratings
Ovid Therapeutics: Promising Pipeline and Strategic Developments Justify Buy Rating
4M ago
Ovid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
Premium
Ratings
Ovid Therapeutics: Promising Pipeline and Financial Stability Drive Buy Rating
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100